Clinical Trial Update: Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ianalumab added to standard-of-care in systemic lupus erythematosus (SIRIUS-SLE 2) is active/not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Ianalumab (ianalumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Systemic Lupus Erythematosus | Phase 3 | Status: ACTIVE_NOT_RECRUITING